Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 2.8/5
Swedish Orphan Biovitrum AB (SOBI SS)
Watchlist
6
Analysis
Health Care
•
Sweden
Swedish Orphan Biovitrum AB (SOBI) operates as a bio-pharmaceutical and bio-technology company. The Company develops therapies and drugs for the treatment of haemophilia, inflammation, and genetic diseases. SOBI serves clients worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Swedish Orphan Biovitrum AB
•
18 Jun 2025 12:41
Swedish Orphan Biovitrum AB: Strategic Launches
Swedish Orphan Biovitrum AB (Sobi), a pharmaceutical company specializing in the treatment of rare diseases, presented its Q1 2025 results.
Baptista Research
Follow
197 Views
Share
bearish
•
Taiwan Stock Exchange Weighted Index
•
30 Aug 2024 16:53
Expecting Downside Ahead; Stick With Defensives; Downgrading Taiwan to Market Weight; Risk-Off Signs
Expecting Downside Ahead $ACWI $SPX; Stick With Defensive Sectors; Downgrading Taiwan $EWT $TSM to Market Weight; Global Discretionary vs. Staples...
Vermilion Research
Follow
425 Views
Share
bullish
•
Petroleo Brasileiro
•
05 Jan 2024 19:50
Buys Within Global Energy, Health Care, and Utilities; Bullish Outlook Intact on Global Equities
Seeing a clear shift into value and defensives, and we recommend adding exposure to these areas globally. Constructive if supports hold: $98-99 on...
Vermilion Research
Follow
535 Views
Share
bullish
•
Swedish Orphan Biovitrum AB
•
12 Sep 2021 19:22
Advent & GIC/SOBI: Awaiting a Sweetened Offer
Median implied valuation across multiples is SEK 246.71/share, c. 5% above offer price. I believe that the offer from the bidding consortium may be...
Jesus Rodriguez Aguilar
Follow
386 Views
Share
bullish
•
MSCI ACWI Index
•
19 Feb 2020 23:53
Global Equity Strategy: Buy the Dips
Despite recent weakness across global markets, our weight of the evidence approach continues to lead us to the same conclusions as we posited in...
Vermilion Research
Follow
470 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.54.8
x